Elena Tenti, Cristina Papayannidis, Giovanni Marconi, Sarah Parisi, Giorgia Simonetti, Stefania Paolini, Chiara Sartor, Emanuela Ottaviani, Nicoletta Testoni, Giovanni Martinelli
Therapy for acute myeloid leukemia (AML) in elderly populations (>65 years) is still a challenge for scientists and hematologists worldwide, and represents an urgent medical need. Notably, the identification and the recognition of molecular and epigenetic mechanisms involved in the pathogenesis of such a heterogeneous disease, are providing new tools for a more successful and 'targeted' approach. Azacitidine is a hypomethylating agent (HMA) with relevant activity in patients affected by myelodysplastic syndrome (MDS) and AML with low blast cells percentage (>30%), in terms of reduction of transfusion dependence, and improvement of quality of life...
December 2016: Expert Opinion on Pharmacotherapy